vimarsana.com

Page 2 - புதியது ப்ராடக்ட்ஸ் மற்றும் சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mila Inc Reports 35 Percent Increase in Smart Home Installations During Lockdowns

Press release content from Business Wire. The AP news staff was not involved in its creation. Mila Inc. Reports 35 Percent Increase in Smart Home Installations During Lockdowns April 20, 2021 GMT ZÜRICH (BUSINESS WIRE) Apr 20, 2021 Mila Inc., the European leader in on demand technical support, reported a 35 percent increase in smart home installations and a tenfold increase in remote tech support consultations for troubleshooting and installations year-to-year from March 2020 to March 2021. Mila serves customers in four European countries and the UK and saw an increase across their customer base of residential, small businesses, and enterprise customers supporting employees working from home. The company pivoted to ramp up its remote support services as lockdowns and shutdowns of their retail partners dragged on.

BlackSky Increases Capacity as Latest Satellite Enters Commercial Operations

Future FinTech Announces the Closing of the Acquisition of Sichuan Ticode Supply Chain Management Co , Ltd

Press release content from PR Newswire. The AP news staff was not involved in its creation. Future FinTech Announces the Closing of the Acquisition of Sichuan Ticode Supply Chain Management Co., Ltd. April 19, 2021 GMT NEW YORK, April 19, 2021 /PRNewswire/ Future FinTech Group Inc. (NASDAQ: FTFT) (“hereinafter referred to as Future FinTech”, “FTFT” or “the Company”), a leading blockchain e-commerce company and a service provider for financial technology, today announced that on April 16, 2021, the Company closed its acquisition of a 60% equity interest in Sichuan Ticode Supply Chain Management Co., Ltd. (“Ticode”) from Sichuan Longma Electronic Technology Co., Ltd. (“Longma”). As previously announced in the Company’s press release on March 1, 2021, the Company and its wholly-owned subsidiary, Future Supply Chain Co., Ltd., entered into a definitive share exchange agreement (the “Agreement”) with Longma and Ticode to acquire a 60% equity interest in Tico

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the . NyxoahApril 19, 2021 GMT Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place aft

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple

Press release content from Globe Newswire. The AP news staff was not involved in its creation. European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple . SanofiApril 19, 2021 GMT European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies Sarclisa combination therapy was associated with undetectable levels of multiple myeloma (MM) in nearly 30% of patients with relapsed MM Second EU approval in less than 12 months for Sarclisa in combination with a standard of care regimen for the treatment of relapsed or refractory MM

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.